The proteoglycan repertoire of lymphoid cells

Abstract

Proteoglycans have been studied to a limited extent in lymphoid cells. In this study we have investigated the expression of proteoglycans in B-cells, CD4+ T-cells, CD8+ T-cells, natural killer cells, as well as in nine different cell lines established from patients with lymphoid malignancies. Serglycin was the major proteoglycan expressed at mRNA level by the primary lymphocytes. None of the syndecans or glycpicans was detected at mRNA level in the primary lymphocytes, except for syndecan-4 in CD4+ T-cells and CD8+ T-cells. All lymphoid cell lines expressed serglycin mRNA, as well as one or several members of the syndecan and glypican families. Further, increased synthesis of proteoglycans was found in the cell lines compared to the primary lymphocytes, as well as the presence of heparan sulfate on the cell surface of five of the cells lines. Western blot analysis showed a close correlation between serglycin mRNA level and expression of serglycin core protein. Our results show that serglycin is a major proteoglycan in all the normal lymphoid cells and that these cells carry little, or none, proteoglycans on the cell surface. Serglycin was also a major proteoglycan in the malignant lymphoid cells, but these also expressed one or more types of cell surface proteoglycans. Thus, malignant transformation of lymphoid cells may be followed by increased synthesis of proteoglycans and expression of cell surface proteoglycans.

Burkitt lymphoma expresses oncofetal chondroitin sulfate without being a reservoir for placental malaria sequestration

“…The samples were incubated with biotinylated rVAR2, potential rVAR2 binding proteins were isolated using streptavidin-coated magnetic beads and identified by Mass Spectrometry (Table 2). All cell lines expressed multiple rVAR2-bound CSPGs in line with a previous study that showed that malignant lymphoid cells in general express more types of cell-associated proteoglycans than normal lymphocytes (45). Among the hits were several well-known cancer-associated CSPGs such as CD44, CD47, CD74, and APP (46-50).…”

Comparative glycomics of leukocyte glycosaminoglycans

“…In a recent paper , Fadnes et al . demonstrated that the intracellular proteoglycan serglycin mRNA is dominant in lymphocytes, including CD4+ T cells, CD8+ T cells, B cells and NK cells.…”

“…In a recent paper [38], Fadnes et al demonstrated that the intracellular proteoglycan serglycin mRNA is dominant in lymphocytes, including CD4+ T cells, CD8+ T cells, B cells and NK cells. They also showed that no syndecan or glypican mRNA was detected in lymphocytes, except syndecan-4 in CD4+ and CD8+ T cells.…”

Heparan sulfates targeting increases MHC class I- and MHC class II-restricted antigen presentation and CD8 + T-cell response

“…Our binding studies performed with splenocytes show that ZZOva does not bind to T-CD4 + , T-CD8 + and B-lymphocytes, but interacts with CD11c + DCs. When ZZOVA is coupled to Tat22-57S, it remains capable of DC-targeting, but also spreads to the three populations of lymphocytes with a variable efficiency that might be due to differences in HSPG expression [26]. However, spreading does not cause a major impairment of T-cell activation and the HS-ligand has beneficial effects since the amounts of ZZOvaTat22-57S and ZZOvaDTR-BD required to stimulate CD8 + and CD4 + T-cells are approximately 10 times lower than those required for ZZOva.…”